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ABSTRACT
Objective: Polymorphisms in vitamin D receptor (VDR) genes are known to be linked with different metabolic diseases including Type 2 diabetes 
mellitus (T2DM) also. However, the association of these polymorphisms is not much explored for the Indian population. To determine the prevalence 
of BsmI and TaqI polymorphism in VDR gene of T2DM patients from North India.
Methods: Blood samples were obtained from 100 well-characterized T2DM patients and 100 healthy controls. Genomic DNA was isolated from blood 
samples and using polymerase chain reaction/restriction fragment length polymorphism based method, the presence of these polymorphisms was 
investigated in these samples. The data were statistically analyzed using SPSS 21.0 software.
Results: For TaqI polymorphism, both the wild type (TT) and heterozygous (TC) genotype showed a significant difference between patients and 
controls (p=0.023 and p<0.001, respectively). Whereas, the frequency of CC genotype was not significantly different among these groups (p=0.506). 
For BsmI polymorphism also, the frequency of wild type (GG) and heterozygous (GA) genotype was significantly different in patients and controls 
(p=0.027 and p=0.001), respectively. However, the frequency of AA genotype was not of statistical significance in patients (p=0.071).
Conclusions: The mutant alleles of TaqI and BsmI polymorphisms are known to be associated with different metabolic diseases, including diabetes 
too. In our study also, there is a significant difference between the frequency of wild type and heterozygous genotype for these polymorphisms. This 
suggests that BsmI and TaqI polymorphisms may be associated with T2DM patients.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is one of the most prevalent lifestyle 
diseases, which is characterized by the high blood glucose levels 
resulting from defects in insulin action. It usually initiates with insulin 
resistance, a disorder in which the cells do not respond to insulin 
properly and increases the risks of many other diseases [1]. According 
to the International Diabetes Federation by 2035, worldwide the 
number of T2DM patients is estimated to exceed more than 600 million. 
India is known as a capital of diabetes, shelter to more than 63 million 
people suffering from diabetes, expected to increase to 100 million by 
2030 [2]. This increase in the T2DM patient is matter of serious concern. 
Being a complex disease, T2DM is known to be caused by a large 
number of environmental and genetic factors too. The role of vitamin 
D in the pathogenesis and prevention of DM has sparked widespread 
interest. Apart from its classical role in Ca++ homeostasis, vitamin D 
also regulates insulin secretion from beta cells and its action on various 
target cells too [3-8]. All the vitamin D-mediated signaling is entirely 
dependent on its binding with the vitamin D receptors (VDR), which 
are present on the surface of the nuclear membrane. VDR, after binding 
with vitamin D, acts as active transcription factors, which controls the 
expression of approximately 200 genes including insulin too. Hence, 
variations/mutation in VDR gene is known to affect the insulin level, 
leading to diabetes [9-11]. 
Several polymorphisms in VDR gene have been reported to be associated 
with various metabolic diseases [12-15]. From last decade, these 
polymorphisms are also reported in different diabetic populations [16]. 
It has been hypothesized that VDR polymorphisms may influence both 
the risk of occurrence of diabetes and its prognosis too [17]. Out of all 
the reported VDR polymorphisms which are known to be associated 
with diabetes, four allelic variants have been commonly identified 
and described in great detail. These polymorphisms are rs731236 
(TaqI), rs1544410 (BsmI), rs7975232 (ApaI), and rs10735810 (Fok1). 
These four single nucleotide polymorphisms were identified using 
TaqI, BsmI, ApaI, and FokI restriction enzymes, respectively. The TaqI 
polymorphism is located at exon 9 (T65058C bp), codon 352. Although 
this is a synonymous change, it is reported to be associated with lower 
circulating levels of active vitamin D3 [18-20]. BsmI is present in intron 
8 (63980 bp) at the 3’ end, and being an intronic polymorphism, do 
not change the amino acid sequence of the encoded protein, but they 
may affect the expression of VDR gene by regulating the stability 
of mRNA [21]. Different research groups observed that both these 
polymorphisms, either independently or together, are associated with 
insulin resistance and increase in the fasting glucose levels [22,23]. 
In contrary, Ye et al., Malecki et al., and Cyganek et al. examined that 
there was no significant association of these polymorphisms with 
T2DM [24-26]. The status of association of these polymorphisms is 
also not very clear in context to the Indian population as there are very 
few reports available which highlight their association with diabetic 
phenotype in India [27]. Hence, the present work aims at investigating 
the association of the TaqI and BsmI polymorphism of VDR gene in 
T2DM patients from North India.
METHODS
Study population
A total of 100 T2DM patients and respective 100 controls were selected 
for the study. All the participants were recruited from All Indian Institute 
of Medical Sciences (AIIMS), New Delhi, India. These participants were 
between the ages of 35 and 55 years, non-smokers and belonged to the 
same ethnic group. T2DM patients were diagnosed on the basis of ADA 
Guidelines (2012). Individuals with fasting glucose ≥126 mg/dl and 
postprandial glucose ≥200 mg/dl were classified as diabetic. However, 
healthy controls with no metabolic disease were considered as controls. 
The present study was approved by the ethical committee of AIIMS, 
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New Delhi, India. The blood samples and clinical details were collected 
after taking the informed consent from all the participants.
Genomic DNA extraction
About 2 ml of the blood sample was collected in ethylenediamine tetra 
acetic acid coated BD Vacutainer and extraction of total genomic DNA 
was performed using the standard protocol of salting out method [28]. 
DNA extracted was stored at −80°C for further experiments.
Genotyping/polymerase chain reaction (PCR)-restriction 
fragment length polymorphism (RFLP)
To do genotyping by RFLP, a region of 745 and 155 bp carrying the 
restriction sites of TaqI and BsmI, was amplified by PCR. The specific 
PCR products were digested with TaqI and BsmI restriction enzyme. 
For amplification of VDR gene segments containing TaqI and BsmI 
restriction sites, the published primers were used (Table 1).
PCR amplification was carried out using the Biorad DNA Engine Thermal 
Cycler (PTC0200), the reaction mix was prepared using 50 ng of DNA, 10 
pmol of both the forward (F) and reverse (R) primers (Sigma-Aldrich), 
2 mM of dNTP’s (Sigma-Aldrich), 0.5U Taq polymerase (Sigma-Aldrich), 
and nuclease-free water was used to make volume to 20 µl. PCR 
conditions were initial denaturation at 95°C for 5 minutes; 30 cycles of 
denaturation at 95°C for 1 minute; annealing at 68°C/63°C (TaqI/BsmI) 
for 1 minute; extension at 72°C for 1 minute followed by final extension 
at 72°C for 5 minutes. The PCR product of 745 and 155 bp was digested 
with 10 unit of each TaqI (65°C for 4 hrs, Thermo Scientific) and BsmI 
(37°C for 4 hrs, Thermo Scientific) restriction enzyme, respectively. 
These digested products were then resolved in 4% agarose gel stained 
with ethidium bromide using gel electrophoresis system at 100 V for 
1-2 hrs. The gel was visualized under ultraviolet light using BioRad gel 
doc system.
As per the different genotypes for each polymorphism, the expected 
size of fragments obtained after digestion with TaqI and BsmI are 
mentioned in Table 1.
Statistical analysis
The statistical analysis was performed using a commercially available 
software program (SPSS 21.0, SPSS Inc., Chicago, Illinois, USA). The 
difference in allelic and genotypic frequencies was compared, using the 
Chi-square (χ2) tests. Results were analyzed by calculating the p value 
and 95 confidence intervals. p values with <0.05 were considered to be 
statistical significant.
RESULTS
General characteristics of study population
The mean age of T2DM patients was 46.8±11.33 years, and it was 
observed to be 39.34±11.12 years for the control group. Among all 
the T2DM patients, the average fasting glucose level was found to be 
158.25±48.85 mg/dl, whereas postprandial plasma glucose level was 
235.57±86.0 mg/dl.
Distribution of TaqI and BsmI polymorphisms in VDR gene
For TaqI polymorphism, genotype frequencies were TT (36%), TC 
(54%), and CC (10%) in patients and TT (50%), TC (37%), and CC 
(13%) in controls. It indicated that out of 3 genotypes, the heterozygous 
genotype was the most common in patients. On the other hand, the 
wild type genotype was the most common type in control. In both the 
groups, the mutant profile was less prevalent (Table 2).
As a result of statistical analysis, the frequency of TT and TC genotype 
of TaqI polymorphism showed a significant difference between 
patients and controls (p=0.023 and p<0.001, respectively). Whereas 
the frequency of mutated profile (CC) was not significantly different 
among these two groups, with χ2=0.442, p=0.506 (Table 2). After 
the comparison of the frequency of mutant allele (C), there was 
no significant difference observed between patients and controls 
(χ2=1.100, p=0.294) (Table 3).
Analysis of different genotypes of BsmI revealed that frequency 
of genotypes was GG (20%), GA (56%), and AA (24%) in patients 
and GG (9%), GA (77%), and AA (14%) for controls. Here again, the 
heterozygous genotype was most common in both the groups, but 
its frequency was higher in controls. Unlike TaqI, the least common 
genotype in both groups was found to be wild type genotype (Table 4).
As similar to TaqI polymorphism, the frequency of wild type (GG) and 
heterozygous genotype (GA) of BsmI was also found to be significantly 
different in patients and controls (χ2=4.88, p=0.027 and χ2=10.945, 
p=0.001). However, the frequency of mutated profile (AA) was not 
different among these two groups of individuals (χ2=3.249, p=0.071) 
(Table 4). Moreover, allelic frequency of mutant allele (A) was also 
found to be same in patients and controls (χ2=0.020, p=0.887) (Table 5).
DISCUSSION
The importance of studying polymorphisms in the VDR gene 
initially emerges due to ethnic differences among different 
populations [18-20,31,32]. However, later it was also found 
to be associated with different metabolic diseases including 
diabetes [12-14,21-26]. As VDR gene is expressed in different types 
of tissues including pancreatic β-cells and adipocytes [33,34], which 
supports the idea that VDR polymorphisms possibly affects the insulin 
secretion and glucose metabolism [35,36].
In recent years, the relevance of VDR polymorphism has been 
investigated by a large number of studies in T2DM patients from 
different populations. The observations of different studies were not 
same. Most of the VDR gene polymorphism-related studies suggested a 
significant association between heterozygous and/or mutant genotype 
with different clinical parameters of diabetes such as glucose levels, 
obesity, and insulin level. For example, the study of BsmI polymorphism 
in T2DM patients done by Ortlepp et al. suggests a significant 
association of BsmI with fasting glucose levels of 1539 T2DM patients 
(p=0.018) [22]. Similarly, Oh et al. investigated BsmI polymorphisms 
and found a significant association with insulin levels of the 1545 T2DM 
patients, p<0.05 [36]. A study by Al-Daghri et al. found that TaqI and 
BsmI polymorphisms are significantly associated with T2DM n=627, 
p=0.033 [37]. On the similar lines, Ogunkolade et al. found a significant 
association of TaqI and insulin secretion in 143 Bangladeshi Asians 
(p<0.001) [32]. However, on the other hand, there are studies which 
contradict the same. For instance, the study by Bid et al., 2009, 
Table 1: Details of primer sequences and fragment lengths obtained after digestion of PCR products with TaqI and BsmI restriction 
enzymes




TaqI Exon 9 (65058) rs731236 T/C F5’CAGAGCATGGACAGGGAGCAA-3’ 
R5’GCAACTCCTCATGGCTGAGGTCTC-3’ [29]
68°C 745 TT/494, 251
CC/293, 251, 201
TC/494, 293, 251, 201
BsmI Intron 8 (63980) rs1544410 G/A F-5’GTGTGCAGGCGATTCGTA -3’
R5’TACCCTGCCCGCAAGAAA -3’[30] 
63°C 155 GG/80, 70, AA/155, 
GA/155, 80, 70
PCR: Polymerase chain reaction, SNP: Single nucleotide polymorphisms, RFLP: Restriction fragment length polymorphism
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observed a non-significant association between any of common VDR 
polymorphisms (FokI, BsmI, and TaqI) and risk of T2DM [27]. Malecki 
et al. also studied VDR polymorphisms (Fok1, ApaI, BsmI, and TaqI) in 
Polish population and showed no association of these polymorphisms 
with T2DM [25]. Cyganek et al. did the same study in 267 T2DM patients 
of Poland, and there was no association found with the T2DM [26]. In 
1998, Hitman et al. studied ApaI, BsmI, and TaqI in 164 T2DM patients 
and observed a non-significant association of BsmI and TaqI with 
T2DM [17].
In context to the Indian population, there is scarcity of the data 
which may support either of the view for VDR polymorphisms and its 
association with diabetes. Thus, in the current study, we have analyzed 
two common VDR gene polymorphisms; TaqI and BsmI in T2DM 
patients from North India. TaqI polymorphism is a silent substitution 
thus does not account for an amino acid change in VDR protein [32]. 
However, the wild type TT genotype of TaqI polymorphism is known to 
be associated with high copy number of VDR mRNA [17,32]. Hence, it 
may be hypothesized that the patients lacking wild genotype may have 
low copies of VDR gene transcripts which may probably affect level of 
VDR protein, and hence, the glucose metabolism too. In our study, the 
patient group had significantly a low number of wild type genotype TT, 
and it was found in only 36% of patients as compared to 50% of 
controls. The heterozygous TC genotype of TaqI polymorphism also 
shows a significant difference between T2DM patients and controls, 
further highlighting the possible role of mutant allele in determining 
the copy number of VDR gene transcript. The mutant profile (CC) of 
TaqI polymorphism was equally distributed in both the groups of 
individuals.
BsmI is an intronic polymorphism and proposed to affect the stability of 
VDR transcript [38]. It has also been demonstrated that an association 
exists between the BsmI polymorphisms of VDR gene and low insulin 
secretion in T2DM patients [17]. The study conducted by Speer et al. 
also showed that there is a link between heterozygous genotype of 
BsmI polymorphisms and T2DM in the Caucasian population [39]. 
In the similar context, we have also observed that the frequency of 
heterozygous GA genotype was significantly different among patients 
and controls (p=0.001). As similar to TaqI, we observed the significant 
difference between the frequency of wild type genotype between 
patients and controls, but surprisingly, the wild type genotype was 
higher in patients and heterozygous genotype was higher in controls. In 
addition, the mutant profile showed no difference between two groups 
of individuals as similar to TaqI data.
Comparison of frequency of mutant allele for both the polymorphisms 
indicated that there is no significant difference between patients and 
controls, however, to validate the same a large scale study design is 
required.
CONCLUSION
Both these polymorphisms are proposed to influence the transcription 
and/or stability of mRNA of VDR gene. Hence, based on our study and 
results from published literature, it can be proposed that TaqI and BsmI 
VDR polymorphisms may be associated with T2DM. Moreover, VDR 
signaling is also known to be important for insulin secretion and its 
action on the target cell. Hence, these polymorphisms may be suggested 
to be associated with altered insulin secretion and/or action, further 
contributing to the development of T2DM.
Although these two polymorphisms are not the only polymorphisms of 
VDR gene, known to be associated with T2DM, we propose to study the 
role of other VDR polymorphisms in these patients.
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